← Back to Clinical Trials
Recruiting NCT05177523

NCT05177523 Imaging the Interplay Between Axonal Damage and Repair in Multiple Sclerosis

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05177523
Status Recruiting
Phase
Sponsor University Hospital, Basel, Switzerland
Condition Multiple Sclerosis (MS)
Study Type OBSERVATIONAL
Enrollment 300 participants
Start Date 2018-09-04
Primary Completion 2028-12

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 80 Years
Study Type OBSERVATIONAL
Interventions
MRINeurocognitive examination for healthy subjectsblood sampling

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 300 participants in total. It began in 2018-09-04 with a primary completion date of 2028-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This project is to: 1. Quantify differences in axonal integrity and organization in aMS versus naPMS patients. 2. Quantify changes in axonal integrity and organization in aMS versus naPMS patients over a two-year period. 3. Validate the combination of imaging parameters that best differentiate aMS versus naPMS patients using histopathology.

Eligibility Criteria

Inclusion Criteria for patients: * Patients may be diagnosed with: 1. active RRMS (n=100): Relapsing-remitting course and \> 1 clinical relapse and/or signs of MRI activity (\> 1 Gd enhancing lesion) during the last year before study enrollment. 2. non-active PMS (n=100): Progressive course (PPMS or SPMS) and no clinical relapses and/or signs of MRI activity during the last year before study enrollment. * Age 18-80 years old * No other neurological or psychiatric disorder Inclusion criteria for healthy controls: * Age 18-80 years old * No other neurological or psychiatric disorder Exclusion Criteria for patients and healthy controls: * Pregnancy * Contraindication to MRI (eg, claustrophobia, metallic implants, pacemaker etc). * Inability to give consent

Contact & Investigator

Central Contact

Cristina Granziera, Prof. Dr. med.

✉ cristina.granziera@usb.ch

📞 +41 61-32 85 665

Principal Investigator

Cristina Granziera, Prof. Dr. med.

PRINCIPAL INVESTIGATOR

Department of Neurology, University Hospital Basel

Frequently Asked Questions

Who can join the NCT05177523 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Multiple Sclerosis (MS). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05177523 currently recruiting?

Yes, NCT05177523 is actively recruiting participants. Contact the research team at cristina.granziera@usb.ch for enrollment information.

Where is the NCT05177523 trial being conducted?

This trial is being conducted at Basel, Switzerland.

Who is sponsoring the NCT05177523 clinical trial?

NCT05177523 is sponsored by University Hospital, Basel, Switzerland. The principal investigator is Cristina Granziera, Prof. Dr. med. at Department of Neurology, University Hospital Basel. The trial plans to enroll 300 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology